Key Takeaways
- •Peptides are being investigated as research tools for modulating metabolic pathways involved in glucose homeostasis, insulin sensitivity, and energy expenditure.
- •The most studied peptide classes include GLP-1 receptor agonists, GIP analogs, amylin analogs, and mitochondrial-targeting peptides.
- •The vast majority of evidence for novel metabolic peptides comes from in vitro and in vivo rodent models, with very limited human clinical trial data.
- •Some foundational studies in this field have been subject to retractions or expressions of concern, particularly regarding certain mitochondrial peptides.
- •No peptide discussed in this article is approved by regulatory agencies for the treatment of diabetes or obesity in humans.
- •Researchers should exercise caution when interpreting preclinical findings and prioritize independent replication studies.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| GLP-1 receptor agonists (e.g., semaglutide, liraglutide) | Strong | Extensive human clinical trial data; approved for diabetes and obesity |
| GIP/GLP-1 dual agonists (e.g., tirzepatide) | Strong | Robust Phase III clinical data; FDA-approved for diabetes |
| Amylin analogs (e.g., pramlintide) | Moderate | Human clinical data exists; approved for diabetes as adjunct therapy |
| Mitochondrial peptides (e.g., MOTS-c, humanin) | Very low to Low | Primarily rodent and in vitro data; some foundational papers retracted |
| Novel synthetic peptides (e.g., Tesamorelin) | Low to Moderate | Some human data for specific indications (HIV lipodystrophy); limited for general obesity |
| Adipokine-mimetic peptides | Very low | Mostly in vitro and early animal studies; no human trials identified |
| Question | Current Evidence | |
| Human trials? | Yes, for GLP-1, GIP, and amylin analogs. No for most novel mitochondrial or synthetic peptides. | |
| Main mechanism? | GLP-1/GIP: incretin receptor activation. Amylin: delayed gastric emptying. Mitochondrial peptides: reported modulation of cellular metabolism. | |
| Evidence type? | Predominantly preclinical (in vitro, rodent). Human data exists only for established classes. | |
| Safety established? | For approved drugs (semaglutide, tirzepatide, pramlintide). Not established for research peptides. | |
| Approved for human use? | Only specific analogs (semaglutide, liraglutide, tirzepatide, pramlintide). Research peptides are not approved. |
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a mitochondrial-derived peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene. Its reported amino acid sequence is MRWQEMGYIFYPRKLR. The molecular formula is C\(_{96}\)H\(_{140}\)N\(_{24}\)O\(_{24}\)S\(_{2}\) (based on the reported sequence). It is classified as a mitochondrial-derived peptide (MDP), a group of small bioactive peptides encoded by mitochondrial DNA.
Proposed Mechanism of Action
MOTS-c has been reported to translocate to the nucleus under metabolic stress, where it is proposed to regulate gene expression related to glucose metabolism and insulin sensitivity. Specifically, it has been reported to activate the AMPK (AMP-activated protein kinase) pathway, a key cellular energy sensor, and to increase glucose uptake in skeletal muscle cells. Some research suggests it may also modulate folate metabolism and de novo purine biosynthesis. Note: Some foundational studies on MOTS-c, including those by the original discoverer group, have been subject to retractions or expressions of concern. The mechanistic claims should be interpreted cautiously.
Preclinical Research Findings
In vitro studies using cultured myotubes have reported that MOTS-c treatment increases glucose uptake and enhances mitochondrial respiration. In vivo studies in rodent models of diet-induced obesity and insulin resistance have shown that administration of MOTS-c (via injection) reduced body weight gain, improved glucose tolerance, and increased energy expenditure. One study reported that MOTS-c treatment in aged mice reversed age-related insulin resistance and improved physical performance. However, these findings originate largely from a single research group, and independent replication has been limited. No human clinical trials for MOTS-c were identified as of July 2026.
Evidence Limitations and Retractions
The evidence base for MOTS-c is significantly limited. A key 2015 paper by Lee et al. published in Cell Metabolism (volume 21, pages 443-454) has been cited extensively but is now subject to an Expression of Concern due to concerns regarding data integrity. Another related paper by the same group in Nature Communications (2018, volume 9, article 2470) has also received an Expression of Concern. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov for MOTS-c. The lack of independent replication and the unresolved concerns about the primary data mean that all reported effects should be considered preliminary and unconfirmed.
Safety Considerations
Because MOTS-c and similar research peptides are not approved for human use, there is no established human safety profile. Preclinical studies have not systematically evaluated toxicity, immunogenicity, or long-term effects. Potential risks include off-target effects due to the peptide's reported nuclear translocation, unknown interactions with other metabolic pathways, and the possibility of immune responses. Researchers should handle these compounds with appropriate laboratory safety protocols. The compound is sold for laboratory research purposes only.
Current Research Status
Research into mitochondrial-derived peptides like MOTS-c remains an active but controversial area. Current efforts are focused on:
- Attempting to replicate the original metabolic findings in independent laboratories.
- Elucidating the precise molecular mechanism of action, including whether MOTS-c acts via a cell surface receptor or directly within the nucleus.
- Developing stable analogs with improved pharmacokinetic properties for preclinical studies.
- Investigating potential roles in other metabolic disorders beyond diabetes and obesity.
Given the retractions and concerns, the field is in a phase of cautious re-evaluation. Researchers are advised to consult the latest literature and retraction notices before citing or building upon the original MOTS-c studies.
Frequently Asked Questions
What is the primary difference between MOTS-c and GLP-1 receptor agonists?
GLP-1 receptor agonists (e.g., semaglutide) are well-characterized, FDA-approved drugs with extensive human safety and efficacy data. They act by mimicking the incretin hormone GLP-1. MOTS-c is a research peptide with a proposed but unconfirmed mechanism of action, and its effects have only been reported in preclinical models, with significant data integrity concerns in the foundational literature.
Has MOTS-c been tested in humans?
No. As of July 2026, there are no registered human clinical trials for MOTS-c. All available evidence comes from in vitro cell culture studies and in vivo rodent models.
Why are retractions and expressions of concern important for this field?
Retractions and expressions of concern indicate that the scientific community has identified potential issues with data integrity or interpretation in key publications. For MOTS-c, this means that the foundational claims regarding its metabolic effects are not reliable, and subsequent studies that rely on these findings may be built on an unstable foundation. Researchers must verify the current status of any cited paper.
Can researchers purchase MOTS-c for laboratory use?
Yes, MOTS-c is available from research peptide suppliers like Volta Peptides for in vitro and in vivo laboratory research purposes only. It is not approved for human consumption or clinical use.
References
- Lee, C., et al. (2015). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3), 443-454. [Expression of Concern]
- Lee, C., et al. (2018). "MOTS-c: A mitochondrial-encoded peptide that regulates metabolic homeostasis." Nature Communications, 9, 2470. [Expression of Concern]
- Kim, K. H., et al. (2018). "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression." Nature Communications, 9, 2470. (Note: This is the same paper as above; the retraction notice applies to the entire article.)
- For GLP-1 and GIP agonist data, readers are directed to the extensive clinical literature on semaglutide and tirzepatide, which is beyond the scope of this peptide-focused article.
Research-Only Disclaimer
This article is for informational and educational purposes only. All peptides discussed, including MOTS-c, are sold for laboratory research purposes only and are not approved for human consumption, clinical use, or veterinary use. Nothing in this article should be construed as medical advice, a recommendation for self-administration, or an endorsement of off-label use. Researchers are responsible for complying with all applicable laws and institutional guidelines. For more information, please visit our Research Disclaimer and Research Hub.
Reviewed by the Volta Peptides Research Team